Rui Yang, MD
- Orthopaedic Surgery
- Practice Specialty
- Orthopaedic Surgery, Oncology
- Medical Education
- Beijing Medical University
- Peking University People's Hospital, University of Texas
- Memorial Sloan Kettering Cancer Center
- Main Location
- Academic Title
- Assistant Professor, Orthopaedic Surgery
- Administrative Title
- Attending Physician, Orthopaedic Surgery
- Clinical Focus
Diagnosis and treatment of benign and malignant tumors in the musculoskeletal system.
- Research Focus
Musculoskeletal tumors, the tumorigenesis of osteosarcoma, the genetic profile of the tumors as comparison to normal counterpart tissues.
View Dr. Yang’s publications on PubMed and Einstein
Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential.
Li N, Yang R, Zhang W, Dorfman H, Rao P, Gorlick R. Cancer. 2009 Oct 15;115(20):4795-806. doi: 10.1002/cncr.24519.
Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma.
Yang R, Hoang BH, Kubo T, Kawano H, Chou A, Sowers R, Huvos AG, Meyers PA, Healey JH, Gorlick R. Int J Cancer. 2007 Sep 1;121(5):943-54.
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway.
Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R. Cancer Res. 2004 Apr 15;64(8):2734-9.
Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in humanosteosarcoma.
Nathan SS, DiResta GR, Casas-Ganem JE, Hoang BH, Sowers R, Yang R, Huvos AG, Gorlick R, Healey JH. Clin Cancer Res. 2005 Mar 15;11(6):2389-97.
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma.
Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. Clin Cancer Res. 2005 Apr 1;11(7):2561-7.
Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R. Int J Cancer. 2004 Mar;109(1):106-11.
Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Yang R, Piperdi S, Gorlick R. Clin Cancer Res. 2008 Oct 15;14(20):6396-404. doi: 10.1158/1078-0432.CCR-07-5113.
Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. Yang R, Li WW, Hoang BH, Kim H, Banerjee D, Kheradpour A, Healey JH, Meyers PA, Bertino JR, Gorlick R. BMC Cancer. 2008 May 1;8:124. doi: 10.1186/1471-2407-8-124.
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.
Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, Bernstein M, Beardsley GP, Krailo MD, Devidas M, Bertino JR, Meyers PA, Gorlick R. Clin Cancer Res. 2003 Feb;9(2):837-44.
The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH, Huvos AG, Meyers PA, Gorlick R. Clin Cancer Res. 2007 May 1;13(9):2557-67.
Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas.
Flintoff WF, Sadlish H, Gorlick R, Yang R, Williams FM. BiochimBiophysActa. 2004 Oct 14;1690(2):110-7.
Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma.
Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, Sowers R, DiResta GR, Gorlick R, Healey JH. J Orthop Res. 2008 Nov;26(11):1520-5. doi: 10.1002/jor.20633.
Polymorphisms and methylation of the reduced folate carrier in osteosarcoma.
Yang R, Qin J, Hoang BH, Healey JH, Gorlick R. ClinOrthopRelat Res. 2008 Sep;466(9):2046-51. doi: 10.1007/s11999-008-0323-3. Epub 2008 Jun 5.
Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma.
Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, Sowers R, DiResta GR, Gorlick R, Healey JH. Ann Acad Med Singapore. 2009 Dec;38(12):1041-7.
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30.
Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, Meng Q, Ye ZY, Wang W, Jiang XT, Xu L, He XL, Zhao ZS, Xu WJ, Wang HJ, Ma YY, Xia YJ, Li L, Zhang RX, Jin T, Zhao ZK, Xu J, Yu S, Wu F, Liang J, Wang S, Jiao Y, Yan H, Tao HQ. Eur J Cancer. 2015 May;51(8):969-76. doi: 10.1016/j.ejca.2015.03.010. Epub 2015 Apr 2.
Comparative Effectiveness of Suprascapular Nerve Block in the Relief of Acute Post-Operative Shoulder Pain: A Systematic Review and Meta-analysis.
Chang KV, Wu WT, Hung CY, Han DS, Yang RS, Chang CH, Lin CP. Pain Physician. 2016 Sep-Oct;19(7):445-456.
Dr. Yang is a fellowship trained orthopaedic surgeon recognized for hismulti-disciplinary approach to the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system including metastatic bony lesions as well as primary tumors. He also serves as an Assistant Professor at our Albert Einstein College of Medicine.
Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopaedic residency at Peking University People’s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a Master’s degree in Biological Sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopaedic surgery residency at the University of Texas, in Houston followed by a fellowship in Orthopaedic Oncology at Memorial Sloan-Kettering Cancer Center.
Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumorigenesis of osteosarcoma and the genetic profile of the tumors as comparison to its normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, as well as novel strategies to overcome it in collaboration with pediatric sarcoma teams.